Published in Am J Psychiatry on October 01, 1995
Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Ther (2003) 1.57
Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr Pharm Des (2009) 1.51
Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol Psychiatry (2001) 1.23
How antipsychotics work-from receptors to reality. NeuroRx (2006) 1.12
Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl) (2007) 1.11
5-HT radioligands for human brain imaging with PET and SPECT. Med Res Rev (2011) 1.10
Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis. Neuropsychopharmacology (2009) 1.02
The antipsychotics olanzapine, risperidone, clozapine, and haloperidol are D2-selective ex vivo but not in vitro. Neuropsychopharmacology (2010) 0.92
Clinical pharmacology of atypical antipsychotics: an update. EXCLI J (2014) 0.91
SEP-225289 serotonin and dopamine transporter occupancy: a PET study. J Nucl Med (2011) 0.91
Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry (2005) 0.90
Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia. Schizophr Res (2015) 0.88
α2-Adrenoceptors are targets for antipsychotic drugs. Psychopharmacology (Berl) (2014) 0.88
The serotonergic system in motor and non-motor manifestations of Parkinson's disease. Exp Brain Res (2013) 0.86
Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: a PET study. Psychopharmacology (Berl) (2006) 0.86
Remission of irreversible aripiprazole-induced tardive dystonia with clozapine: a case report. BMC Psychiatry (2015) 0.85
Diverse roles of neurotensin agonists in the central nervous system. Front Endocrinol (Lausanne) (2013) 0.85
Depression and impulsivity as pathways to violence: implications for antiaggressive treatment. Schizophr Bull (2013) 0.85
Comparison of D₂ dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects. Int J Neuropsychopharmacol (2011) 0.84
Topiramate augments the antipsychotic-like effect and cortical dopamine output of raclopride. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.84
Factors associated with response to clozapine in schizophrenia: a review. Psychopharmacol Bull (2011) 0.82
Desipramine enhances the ability of risperidone to decrease alcohol intake in the Syrian golden hamster. Psychiatry Res (2014) 0.82
A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian). Psychopharmacology (Berl) (2005) 0.81
Evaluation of dopamine D₂/D₃ and serotonin 5-HT₂A receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography. Psychopharmacology (Berl) (2012) 0.80
Conventional versus novel antipsychotics: changing concepts and clinical implications. J Psychiatry Neurosci (1999) 0.80
Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacology (Berl) (2009) 0.80
Antipsychotic dosing: found in translation. J Psychiatry Neurosci (2014) 0.79
Clozapine reconstructed: Haloperidol's ability to reduce alcohol intake in the Syrian golden hamster can be enhanced through noradrenergic modulation by desipramine and idazoxan. Drug Alcohol Depend (2015) 0.78
Brain Functional Effects of Psychopharmacological Treatments in Schizophrenia: A Network-based Functional Perspective Beyond Neurotransmitter Systems. Curr Neuropharmacol (2015) 0.78
Positron emission tomographic analysis of dose-dependent NAD-299 binding to 5-hydroxytryptamine-1A receptors in the human brain. Psychopharmacology (Berl) (2003) 0.78
On the discovery and development of pimavanserin: a novel drug candidate for Parkinson's psychosis. Neurochem Res (2014) 0.78
Reboxetine enhances the olanzapine-induced antipsychotic-like effect, cortical dopamine outflow and NMDA receptor-mediated transmission. Neuropsychopharmacology (2010) 0.77
How have developments in molecular imaging techniques furthered schizophrenia research? Imaging Med (2009) 0.77
Prediction of brain clozapine and norclozapine concentrations in humans from a scaled pharmacokinetic model for rat brain and plasma pharmacokinetics. J Transl Med (2014) 0.76
A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration. Psychopharmacology (Berl) (2004) 0.75
Adjunctive treatment with mianserin enhances effects of raclopride on cortical dopamine output and, in parallel, its antipsychotic-like effect. Neuropsychiatr Dis Treat (2005) 0.75
Effects of iloperidone, combined with desipramine, on alcohol drinking in the Syrian golden hamster. Neuropharmacology (2016) 0.75
Dopamine D₂/₃ occupancy of ziprasidone across a day: a within-subject PET study. Psychopharmacology (Berl) (2013) 0.75
Adjunctive treatment with mianserin enhances effects of raclopride on cortical dopamine output and, in parallel, its antipsychotic-like effect. Neuropsychiatr Dis Treat (2005) 0.75
ITI-007 demonstrates brain occupancy at serotonin 5-HT₂A and dopamine D₂ receptors and serotonin transporters using positron emission tomography in healthy volunteers. Psychopharmacology (Berl) (2015) 0.75
Unique receptor-blockading profile of clozapine. Am J Psychiatry (1996) 0.75
The Role of Inhaled Loxapine in the Treatment of Acute Agitation in Patients with Psychiatric Disorders: A Clinical Review. Int J Mol Sci (2017) 0.75
Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors. Int J Neuropsychopharmacol (2015) 0.75
Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future. Curr Top Med Chem (2016) 0.75
Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psychiatry (1999) 2.90
Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry (1992) 2.84
The predictive validity of body mass index based on self-reported weight and height. Int J Obes (1989) 2.65
A comprehensive psychopathological rating scale. Acta Psychiatr Scand Suppl (1978) 2.50
Age-related cognitive deficits mediated by changes in the striatal dopamine system. Am J Psychiatry (2000) 2.12
Chemical brain anatomy in schizophrenia. Lancet (1995) 2.08
EANM procedure guidelines for brain tumour imaging using labelled amino acid analogues. Eur J Nucl Med Mol Imaging (2006) 1.79
Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther (2009) 1.77
Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J Neurosurg (1985) 1.75
Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain. Neurobiol Aging (2000) 1.71
Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET--a comparison to the equilibrium analysis. J Cereb Blood Flow Metab (1989) 1.71
Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science (1986) 1.70
No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone. Psychiatry Res (1995) 1.66
Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC 112 in humans: validation and reproducibility. J Cereb Blood Flow Metab (2000) 1.56
No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457. Am J Psychiatry (2001) 1.49
D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch Gen Psychiatry (1990) 1.42
Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry (1993) 1.41
Acrylamide: a cooking carcinogen? Chem Res Toxicol (2000) 1.40
Preparation of a potential positron emission tomographic radioligand for the dopamine transporter. Eur J Nucl Med (1994) 1.38
Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry (1988) 1.38
Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology (1994) 1.38
Cancer incidence after radiotherapy for skin haemangioma during infancy. Acta Oncol (1995) 1.33
Perinatal origin of adult self-destructive behavior. Acta Psychiatr Scand (1987) 1.29
Limbic reductions of 5-HT1A receptor binding in human temporal lobe epilepsy. Neurology (2004) 1.28
Evidence for a functional beta 3-adrenoceptor in man. Br J Pharmacol (1993) 1.27
Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]way-100635. Brain Res (1997) 1.26
Comparison of the transient equilibrium and continuous infusion method for quantitative PET analysis of [11C]raclopride binding. J Cereb Blood Flow Metab (1998) 1.25
Fluctuations in T-wave morphology and susceptibility to ventricular fibrillation. J Electrocardiol (1984) 1.24
A systematic genomewide linkage study in 353 sib pairs with schizophrenia. Am J Hum Genet (2003) 1.24
Imaging the living human brain: magnetic resonance imaging and positron emission tomography. Proc Natl Acad Sci U S A (1997) 1.22
Quantification of [11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J Cereb Blood Flow Metab (1999) 1.22
Synthesis of L- and D-[methyl-11C]methionine. J Nucl Med (1987) 1.20
Reduced dopamine transporter binding in patients with juvenile myoclonic epilepsy. Neurology (2008) 1.20
Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med (1995) 1.18
D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res (1998) 1.17
Breast cancer risk after radiotherapy in infancy: a pooled analysis of two Swedish cohorts of 17,202 infants. Radiat Res (1999) 1.17
Reproducibility of [11 C]FLB 457 binding in extrastriatal regions. Nucl Med Commun (2001) 1.16
Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain (1997) 1.15
In-vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci. Lancet (1988) 1.15
Regional cerebral oxidative and total glucose consumption during rest and activation studied with positron emission tomography. Acta Physiol Scand (1994) 1.13
Transplantation in Parkinson's disease: two cases of adrenal medullary grafts to the putamen. Ann Neurol (1987) 1.13
PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain (1997) 1.12
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. Br J Cancer (2012) 1.12
Sex differences in extrastriatal dopamine d(2)-like receptors in the human brain. Am J Psychiatry (2001) 1.11
Photic and neural control of the 24-hour norepinephrine rhythm in the rat pineal gland. J Pharmacol Exp Ther (1967) 1.11
A large deletion disrupts the exon 3 transcription activation domain of the BRCA2 gene in a breast/ovarian cancer family. Cancer Res (1998) 1.11
Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology (1998) 1.11
Distribution of adenosine receptors in the postmortem human brain: an extended autoradiographic study. Synapse (1997) 1.09
Effect of chlorpromazine on accumulation and disappearance of catecholamines formed from tyrosine-C14 in brain. J Pharmacol Exp Ther (1968) 1.08
Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am J Psychiatry (1999) 1.08
D2 dopamine receptors and personality traits. Nature (1997) 1.08
Inactivation of promoter 1B of APC causes partial gene silencing: evidence for a significant role of the promoter in regulation and causative of familial adenomatous polyposis. Oncogene (2011) 1.07
Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc Natl Acad Sci U S A (1985) 1.06
D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry (1995) 1.05
PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756. Synapse (1999) 1.05
Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients. Psychopharmacology (Berl) (1995) 1.05
New PET radiopharmaceuticals beyond FDG for brain tumor imaging. Q J Nucl Med Mol Imaging (2012) 1.05
Outcome of reproduction in women irradiated for skin hemangioma in infancy. Radiat Res (1998) 1.02
Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. Neuropsychopharmacology (1997) 1.01
Adrenergic transmission at vasoconstrictor nerve terminals partially depleted of noradrenaline. Acta Physiol Scand (1965) 1.01
Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br J Psychiatry (1985) 1.01
Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease. Neurology (2000) 1.00
Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine. J Comput Assist Tomogr (1983) 1.00
5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology (Berl) (1993) 1.00
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. Ann Oncol (2011) 1.00
Effects of chronic 17beta-estradiol treatment on the serotonin 5-HT(1A) receptor mRNA and binding levels in the rat brain. Synapse (2000) 1.00
Raclopride, a new selective ligand for the dopamine-D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry (1988) 1.00
A PET study of D2 dopamine receptor density at different phases of the menstrual cycle. Psychiatry Res (1998) 0.99
PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride. Psychopharmacology (Berl) (1987) 0.99